Lyell Immunopharma (LYEL) Net Equity Issued and Repurchased (2020 - 2026)

Lyell Immunopharma (LYEL) posted Net Equity Issued and Repurchased of $1.7 million for Q1 2026, up 5239.39% sequentially from -$33000.0 in Q2 2020.

Lyell Immunopharma (LYEL) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends

Lyell Immunopharma has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $1.7 million in Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at $50.0 million, changed N/A from the prior year.
Net Equity Issued and Repurchased grew to $1.7 million in Q1 2026 per LYEL's latest filing, from -$33000.0 in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $1.7 million in Q1 2026 and troughed at $1.7 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	141.90 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Lyell Immunopharma	326.39 Mn	326.39 Mn	-	-

Download Data